The U.S. Data Safety Monitoring Board expressed concern over the possibility that AstraZeneca included outdated information in its COVID-19 vaccine trial results, according to CNBC.
- The health agency said the results may have provided an incomplete view of efficacy, and has urged the company to update the data as soon as possible.
- The National Institute of Allergy and Infectious Diseases (NIAID) said it was notified of concerns late Monday, along with AstraZeneca and the Biomedical Advanced Research.
- White House chief medical advisor Dr. Anthony Fauci, who leads NIAID, said the vaccine is likely “very good” but data could be “outdated” and “misleading.”
- AstraZeneca said the figures were based on a prespecified interim analysis with a data cut-off of February 17. It committed to share primary analysis with the data safety monitoring board and provide the latest efficacy data within the next 48 hours.
- AstraZeneca shares fell nearly 1% on Tuesday’s trading in London, and down 2% in premarket in New York.